PYC pyc therapeutics limited

0.40%

$1.27

They actually did it twice, one mouse in the pilot study (March)...

First 23 Last

Share
Profile

Follow
Akki

35,790 Posts.

555

05/05/16

19:21

Post #: 17689196
Share

Originally posted by lifeistooshort ↑

So my friend had a high level look at the two presentations on that webpage and thinks its promising.

My friend thinks biologics drug delivery is not so much of an issue generally, although PYCs CPPs seem to be better (in vitro). However, there may be a relevance in relation to oncology targets due to (perhaps) the greater concentration of drugs that need to be delivered - basically my friend is not convinced on this point yet. Need to do more research.

The Myc1 - which I presume is PYC's own myc inhibitor - looks good, but based on slide 43 of the Tides pres it doesn't look better than oMyc. However, slide 44 of the same pres suggests PYC's proprietary myc inhibitor may be able to act for a longer period of time within the cell - this could be significant because it ultimately has a bearing on how much drug a patient needs to take i.e. patient compliance.

The results are very interesting but I stress these are in vitro apart from the one mouse model study. If this works in animal models and gets itself to an IND Phase 1 - that would be fantastic!

My personal view is (and my friend agrees) that if PYC can inhibit myc, then they are about to crack the holy grail in oncology and based on these presentations, they are a few steps forward from where they were mid last year.

I'm a bit annoyed that PYC has not released these presentations to the ASX after they have visited the scientific meetings.

Expand

"The results are very interesting but I stress these are in vitro apart from the one mouse model study."

Expand

They actually did it twice, one mouse in the pilot study (March) and then repeated with a larger number of subjects (November). Not sure how many it was as not specifically stated in the release when trying to track back but I think it was 3 ?

http://stocknessmonster.com/news-item?S=PYC&E=ASX&N=714454

http://stocknessmonster.com/news-item?S=PYC&E=ASX&N=741316

"The objective of the experiment was to extend the initial pilot using larger numbers of animals to establish greater statistical significance."

Expand

PYC Price at posting: 1.4¢ Sentiment: None Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

First 23 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.27		Change 0.005(0.40%)		Mkt cap ! $740.7M

Open	High	Low	Value	Volume
$1.27	$1.29	$1.27	$406.0K	319.3K

Buyers (Bids)

No.	Vol.	Price($)
1	13987	$1.27

Sellers (Offers)

Price($)	Vol.	No.
$1.29	1380	1

View Market Depth

No.	Vol.	Price($)
1	13987	1.265
1	15000	1.260
1	12000	1.255
1	4000	1.225
1	20000	1.220

Price($)	Vol.	No.
1.290	25630	2
1.295	24500	1
1.300	59168	4
1.325	9001	1
1.330	20000	2

Last trade - 16.10pm 27/06/2025 (20 minute delay)

PYC (ASX) Chart

They actually did it twice, one mouse in the pilot study (March)...

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Monash IVF shares cater 25% – Disaster or deep-value play?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

They actually did it twice, one mouse in the pilot study (March)...

Top Stories

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Australia’s gas crisis is here – and dying coal plants aren’t helping

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Monash IVF shares cater 25% – Disaster or deep-value play?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News